Life science research and diagnostics solutions provider Bruker Corporation (Nasdaq:BRKR) announced on Wednesday that it has acquired biosensor development specialist Dynamic Biosensors GmbH (DBS).

DBS's innovative technologies complement Bruker's high-performance Surface Plasmon Resonance (SPR) portfolio, strengthening Bruker's biophysical portfolio for analysing molecular interactions.

DBS develops technologies for studying complex molecular interactions and kinetics, supporting drug discovery in pharma, biotech and research. The acquisition includes the heliXcyto and heliX+ instruments, which offer single-cell Interaction Cytometry (scIC) and switchSENSE technology.

Financial details of the transaction were not disclosed.

Bruker Biosensors expects additional revenues of over USD5m in FY2025, with no material EPS impact.